1356 related articles for article (PubMed ID: 31195981)
1. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
2. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
Liu J; Tang T; Wang GD; Liu B
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
[No Abstract] [Full Text] [Related]
3. Circ_0057558 promotes nonalcoholic fatty liver disease by regulating ROCK1/AMPK signaling through targeting miR-206.
Chen X; Tan QQ; Tan XR; Li SJ; Zhang XX
Cell Death Dis; 2021 Aug; 12(9):809. PubMed ID: 34446693
[TBL] [Abstract][Full Text] [Related]
4. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload.
Wang L; Sun M; Cao Y; Ma L; Shen Y; Velikanova AA; Li X; Sun C; Zhao Y
Arch Biochem Biophys; 2020 Nov; 695():108642. PubMed ID: 33098868
[TBL] [Abstract][Full Text] [Related]
5. microRNA-141 is associated with hepatic steatosis by downregulating the sirtuin1/AMP-activated protein kinase pathway in hepatocytes.
Yousefi Z; Nourbakhsh M; Abdolvahabi Z; Ghorbanhosseini SS; Hesari Z; Yarahmadi S; Ezzati-Mobasser S; Seiri P; Borji M; Meshkani R; Malek M
J Cell Physiol; 2020 Feb; 235(2):880-890. PubMed ID: 31256424
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
Wang LF; Wang XN; Huang CC; Hu L; Xiao YF; Guan XH; Qian YS; Deng KY; Xin HB
Lipids Health Dis; 2017 Apr; 16(1):82. PubMed ID: 28449683
[TBL] [Abstract][Full Text] [Related]
7. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
8. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
[TBL] [Abstract][Full Text] [Related]
9. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
Zhang J; Du H; Shen M; Zhao Z; Ye X
J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
[TBL] [Abstract][Full Text] [Related]
10. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
Xiao Z; Chu Y; Qin W
Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
[TBL] [Abstract][Full Text] [Related]
11. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
12. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
Li Q; Tan JX; He Y; Bai F; Li SW; Hou YW; Ji LS; Gao YT; Zhang X; Zhou ZH; Yu Z; Fang M; Gao YQ; Li M
Int J Biol Sci; 2022; 18(4):1594-1611. PubMed ID: 35280674
[No Abstract] [Full Text] [Related]
13. miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21.
Xiao J; Bei Y; Liu J; Dimitrova-Shumkovska J; Kuang D; Zhou Q; Li J; Yang Y; Xiang Y; Wang F; Yang C; Yang W
J Cell Mol Med; 2016 Feb; 20(2):204-16. PubMed ID: 26648452
[TBL] [Abstract][Full Text] [Related]
14. Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis.
Simão AL; Afonso MB; Rodrigues PM; Gama-Carvalho M; Machado MV; Cortez-Pinto H; Rodrigues CMP; Castro RE
J Mol Med (Berl); 2019 Aug; 97(8):1113-1126. PubMed ID: 31139863
[TBL] [Abstract][Full Text] [Related]
15. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
16. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6.
Huang P; Huang FZ; Liu HZ; Zhang TY; Yang MS; Sun CZ
Metabolism; 2019 May; 94():1-8. PubMed ID: 30711569
[TBL] [Abstract][Full Text] [Related]
17. Down-Regulation of SIRT1 Expression by mir-23b Contributes to Lipid Accumulation in HepG2 Cells.
Borji M; Nourbakhsh M; Shafiee SM; Owji AA; Abdolvahabi Z; Hesari Z; Ilbeigi D; Seiri P; Yousefi Z
Biochem Genet; 2019 Aug; 57(4):507-521. PubMed ID: 30697640
[TBL] [Abstract][Full Text] [Related]
18. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
Yao H; Tao X; Xu L; Qi Y; Yin L; Han X; Xu Y; Zheng L; Peng J
Pharmacol Res; 2018 May; 131():51-60. PubMed ID: 29574225
[TBL] [Abstract][Full Text] [Related]
19. MiR-181b regulates steatosis in nonalcoholic fatty liver disease via targeting SIRT1.
Wang Y; Zhu K; Yu W; Wang H; Liu L; Wu Q; Li S; Guo J
Biochem Biophys Res Commun; 2017 Nov; 493(1):227-232. PubMed ID: 28899784
[TBL] [Abstract][Full Text] [Related]
20. Ablation of systemic SIRT1 activity promotes nonalcoholic fatty liver disease by affecting liver-mesenteric adipose tissue fatty acid mobilization.
Cheng J; Liu C; Hu K; Greenberg A; Wu D; Ausman LM; McBurney MW; Wang XD
Biochim Biophys Acta Mol Basis Dis; 2017 Nov; 1863(11):2783-2790. PubMed ID: 28789977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
